Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Gene Ther. 2008 Aug 14;16(1):60–69. doi: 10.1038/gt.2008.137

Figure 1. In-vivo expression of hFIX from AAV pseudotyped vectors.

Figure 1

Plasma human FIX (hFIX) levels (mean ± SEM) measured by ELISA between days 1 and 57 in mice after tail vein injection of scAAV-LP1-hFIX packaged with capsid derived from serotype -rh.10 (Panel A), -9, (Panel B), -8 (Panel C) and 7 (Panel D) and at different particle doses consisting of 2×1011 (triangle), 4×1010 (circle), 4×109 (diamond) and 4×108 (square) vg/kg. Panel E shows the relationship between vector dose and transgene expression on day 57 for scAAV-LP1-hFIX packaged with capsid derived from serotype -rh.10 (◇), -9, (△), -8 (×) and 7 (○).

HHS Vulnerability Disclosure